Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology. The two parties will leverage their respective resources and strengths to jointly advance the development of next-generation Radionuclide Drug Conjugates (RDCs).

Compared with conventional radiotherapy, RDCs utilise tumour antigen–specific ligands to deliver radionuclides directly to tumour lesions for targeted radiotherapy, thereby effectively reducing damage to surrounding healthy tissues. In contrast to Antibody Drug Conjugates (ADCs), the radionuclides in RDCs can also exert cytotoxic effects on neighbouring tumour cells and the tumour microenvironment, even if those cells do not express the target antigen. This mechanism offers a potential advantage in overcoming tumour heterogeneity and drug resistance. In addition, this technology holds the potential to achieve theranostics—integrating both diagnosis and treatment.

With its advanced technology platforms and deep expertise, Harbour BioMed has built a solid foundation in antibody discovery and development. The company's proprietary Harbour Mice platform enables the generation of fully human monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats, eliminating the need for additional engineering or humanisation. The HCAb technology, in particular, produces unique, fully human heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapeutics. In the development of RDCs, fully human antibodies—characterised by low immunogenicity, superior tissue penetration and high specificity and stability—can significantly enhance the efficiency of targeted delivery, thereby improving therapeutic efficacy while effectively reducing drug-related toxicity and side effects.

Speaking in this regard, Jingsong Wang, MD, PhD, Founder, Chairman and CEO, Harbour BioMed, commented, "We are pleased to establish a long-term strategic collaboration with Lannacheng to jointly advance the development of next-generation RDCs. Harbour BioMed is committed to providing efficient and highly differentiated antibody solutions for innovative therapies through our globally leading Harbour Mice fully human antibody platform. This collaboration will deeply integrate Harbour BioMed's expertise in antibody discovery with Lannacheng's strengths in radiopharmaceutical R&D and commercialisation, accelerating the development of more precise, effective and safe cancer therapies and bringing new hope to patients worldwide."

Founded in 2021, Lannacheng is a clinical-stage biotechnology company dedicated to the discovery, development and commercialisation of integrated theranostic radiopharmaceuticals for oncology. The company's R&D engine, enhanced by its proprietary pharmacokinetic optimisation and dual-targeting drug development platforms, combines target validation, radioisotope selection and linker design to improve pharmacokinetic profiles and advance the development of dual-targeting radiopharmaceutical candidates.

Its strengths are further solidified through end-to-end integration of capabilities supported by its controlling shareholder, Dongcheng Biochem, including R&D resources, a stable supply of radioisotopes, and a GMP production facility currently under construction in Yantai. Together, these elements ensure a sustainable, scalable and rapidly innovating radiopharmaceutical pipeline.

Wu Xiaoming, General Manager, Lannacheng, stated, "We are delighted to establish a long-term strategic collaboration with Harbour BioMed to jointly advance the R&D and translation of next-generation radiopharmaceuticals. Lannacheng is committed to leveraging our systematic radiopharmaceutical technology platform, comprehensive industrial capabilities and global collaboration network to provide efficient, innovative and differentiated integrated solutions for tumour diagnosis and treatment. This collaboration will fully combine Lannacheng's strengths in radiopharmaceutical R&D and commercialisation and Harbour BioMed's deep expertise in antibody discovery. Together, we aim to accelerate the development of more precise, effective and safe cancer treatment therapies, bringing new hope to patients worldwide."